Kenvue Inc. Common Stock (KVUE)

Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on May 27, 2026, to shareholders of record as of the close of business on May 13, 2026.

Kimberly-Clark (KMB) Q1 2026 Earnings Transcript

Kenvue has underperformed the broader market over the past year, and analysts remain skeptical about the stock’s prospects.

Daniel Loeb trims major stake in Kenvue as company advances restructuring and prepares for acquisition by Kimberly-Clark.

Kenvue Inc. (NYSE: KVUE) will announce its first quarter 2026 financial results before the market opens on May 7, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results.

Kenvue will release its first-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

Growth stocks may be on fire again, but if you needed dividend stocks then, you still need them now. Here's a look at three of the best bets at this time.

Decades of dividend increases and a 3% yield make Procter & Gamble a passive-income powerhouse.

Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson don't fall as far as other healthcare stocks and bounce back faster during economic downturns.

Three Dividend Aristocrats offer yields above the 10-year Treasury while delivering income growth and potential capital appreciation

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66

Kimberly Clark is a worthy foundational holding in a passive-income portfolio.

In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of the much-feared "Stelara patent cliff." The healthcare titan announced adjusted earnings per share (EPS) of $2.70 on revenue of $24.1 billion, outpacing

NEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across the board. On April 14, 2026, the healthcare titan announced it was raising its full-year 2026 revenue and earnings guidance, signaling that

As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue, in 2023, the New Brunswick-based giant has shed its "band-aid and baby powder" image to emerge as a high-octane, pure-play healthcare powerhouse. [...]

The choice is based on more than just the dividend payout.

These defensive consumer stocks are flashing buy signals while the market chases AI hype.

As the sun sets on the era of easy profits from elevated interest rates, the titans of Wall Street are preparing to unveil a new chapter in their growth stories. For the first time in three years, the narrative surrounding the upcoming Q1 2026 earnings for Goldman Sachs (NYSE: GS)

This Dividend King drug maker's dividend yield is roughly twice that of the S&P 500 index.

The global financial landscape underwent a seismic shift in the first quarter of 2026, as a "perfect storm" of stabilizing interest rates and technological urgency triggered a historic wave of mergers and acquisitions. Total deal volume for the quarter reached a staggering $1.25 trillion, marking a 26% increase over

Some large merger & acquisition deals that could shake up the consumer goods and the food distribution industry, plus deals in the healthcare industry.

Buying stocks at incredibly low valuations often comes with risk, but it may also result in massive returns.

The first quarter of 2026 has officially marked the end of the deal-making drought, ushering in a lucrative "advisory windfall" for Wall Street’s elite investment banks. Driven by a surge in multi-billion dollar tech and healthcare integrations, total global M&A volume reached a staggering $1.38 trillion in

Shares of Johnson & Johnson have fallen by less than 2% over the past month, while the S&P 500 has fallen by more than 7%.